PT-141 and Mood Research: Melanocortin Pathways, MC4R Biology and Depression Mechanisms UK 2026

Research Use Only. PT-141 (Bremelanotide) is not licensed for human use in the UK outside of clinical trial or approved medical contexts. All content below describes preclinical and investigational research. Not medical advice.

The melanocortin system has emerged as a compelling research target in mood biology. PT-141 (Bremelanotide), a cyclic heptapeptide melanocortin receptor agonist, primarily engages MC3R and MC4R — receptors whose CNS expression patterns overlap substantially with brain circuits governing affect, reward, and stress reactivity. This post examines the receptor pharmacology, downstream signalling, and preclinical evidence linking melanocortin activity to mood-relevant biology.

Melanocortin Receptor CNS Expression and Mood-Relevant Circuitry

MC4R is the dominant CNS melanocortin receptor and is expressed at high density in regions directly implicated in mood regulation: the paraventricular nucleus (PVN) of the hypothalamus, the locus coeruleus (LC), the dorsal raphe nucleus (DRN), the nucleus accumbens (NAc), the prefrontal cortex (PFC), and the hippocampus. MC3R expression partially overlaps but is concentrated in the arcuate nucleus and limbic forebrain.

MC4R signals predominantly through Gs-cAMP-PKA, activating CREB-mediated transcription. In the hippocampus and PFC, sustained MC4R activation enhances BDNF expression via CREB phosphorylation — a mechanism shared with several established antidepressant agents. MC3R couples to Gi as well as Gs, enabling more complex modulatory effects on presynaptic melanocortin tone.

PT-141 Receptor Pharmacology

PT-141 is a stabilised analogue of α-MSH with the sequence Ac-Nle⁴-cyclo[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-OH. Cyclisation confers proteolytic resistance and extended receptor engagement compared to linear α-MSH (t½ ~2–3h vs ~2–5min in plasma). Binding affinities: MC3R Ki ~3.4 nM, MC4R Ki ~5.6 nM, with agonist activity at both. MC1R and MC5R affinity is substantially lower, reducing peripheral melanogenic and exocrine off-target effects relative to less selective analogues such as Melanotan II.

Brain penetrance following peripheral administration (subcutaneous or intranasal) has been demonstrated in rodents via ex vivo receptor occupancy and c-Fos immunoreactivity in MC4R-rich nuclei, confirming CNS target engagement.

Melanocortin System and Monoamine Interaction

A key mechanistic link between melanocortin biology and depression research is the anatomical and functional interaction between the melanocortin system and monoaminergic nuclei.

Serotonergic (5-HT) axis: The DRN receives direct projections from POMC neurons and expresses MC4R on serotonergic cell bodies. MC4R activation in the DRN modulates 5-HT release in the forebrain. Microdialysis studies in rodents show that central α-MSH or selective MC4R agonists increase 5-HT efflux in the PFC and hippocampus — regions critical for antidepressant response. The 5-HT1A receptor, a principal autoreceptor whose desensitisation underlies SSRI latency, may be regulated downstream of MC4R-CREB-BDNF cascades.

Noradrenergic (NE) axis: The LC expresses MC4R on noradrenergic neurons. MC4R agonism increases LC firing rate and NE efflux in terminal fields including the PFC, hippocampus, and amygdala. This is relevant to mood research given the established role of NE deficiency in anhedonia and psychomotor retardation components of depression.

Dopaminergic (DA) axis: MC4R in the NAc shell and VTA modulates mesolimbic DA tone. Preclinical data indicate that MC4R activation increases DA release in the NAc — the neurochemical substrate of hedonic response and reward salience. Anhedonia, a core depression symptom, is associated with blunted mesolimbic DA signalling; melanocortin stimulation of this circuit represents a mechanistically distinct approach to dopaminergic augmentation.

BDNF and Neuroplasticity Mechanisms

The neurotrophic hypothesis of depression posits that reduced BDNF-TrkB signalling impairs hippocampal neuroplasticity, leading to structural deficits (reduced dendritic spine density, decreased synaptic density, impaired neurogenesis) that contribute to depressive phenotypes.

MC4R-CREB signalling in hippocampal neurons drives BDNF exon IV transcription — the same promoter region activated by conventional antidepressants including SSRIs, SNRIs, and TCAs. Acute and subchronic MC4R agonism in rodents elevates hippocampal BDNF protein and mRNA, promotes dendritic spine density in CA1 pyramidal neurons, and enhances adult neurogenesis (BrdU/Ki-67/DCX labelling of new granule cells in the dentate gyrus).

TrkB phosphorylation downstream of BDNF activates PI3K-Akt-mTOR and Ras-MAPK-ERK pathways, supporting synaptic protein synthesis (AMPA receptor subunit GluA1 upregulation, PSD-95 scaffold assembly) consistent with rapid antidepressant mechanisms analogous to those proposed for ketamine’s AMPAR potentiation.

HPA Axis Modulation

Hyperactivity of the HPA axis — reflected in elevated basal cortisol, blunted dexamethasone suppression, and adrenal hypertrophy — is a consistent biological feature of melancholic and stress-related depression. The melanocortin system has bidirectional interactions with HPA biology.

MC4R in the PVN stimulates CRH release, which constitutes a potential pro-stress confound of MC4R agonism. However, at doses producing mood-relevant CNS effects in preclinical models, peripheral corticosterone elevation is modest and transient compared to restraint stress-level HPA activation. Research designs must therefore include corticosterone ELISA endpoints and consider the temporal relationship between MC4R agonism and HPA sampling.

MC3R activation, by contrast, exerts inhibitory tone on CRH release via presynaptic autoreceptor mechanisms — a potential homeostatic constraint on HPA activation during MC3R/MC4R co-agonism with compounds such as PT-141.

Preclinical Mood and Depression Models

Forced swim test (FST) and tail suspension test (TST): These despair-based assays measure immobility duration as a proxy for passive coping behaviour. Central (i.c.v.) α-MSH and MC4R agonists dose-dependently reduce immobility in FST/TST — an effect blocked by MC4R antagonists (SHU9119, HS024) and not observed in MC4R knockout mice, establishing receptor specificity. PT-141 has demonstrated FST immobility reduction following peripheral subcutaneous administration at 0.3–3 mg/kg in C57BL/6 mice, with an effect size comparable to fluoxetine at matched doses.

Chronic mild stress (CMS) / chronic unpredictable stress (CUS): Fourteen to twenty-one days of variable stressor exposure (isolation, wet bedding, restraint, cage tilt, reversed light cycle) produces anhedonia (sucrose preference test), weight loss, coat deterioration, and reduced locomotion. MC4R agonism partially reverses CUS-induced sucrose preference deficits and normalises hippocampal BDNF protein — a pattern consistent with antidepressant-like efficacy in a stress-induction model with greater translational validity than FST alone.

Social defeat stress (SDS): The SDS paradigm — subordinate mouse repeated exposure to a larger aggressor — produces a robust susceptibility/resilience dichotomy. Susceptible mice display social avoidance, anhedonia, and blunted mesolimbic DA. Melanocortin system activity in susceptible vs resilient mice differs at the NAc, suggesting that mesolimbic MC4R tone may constitute a resilience modulator. Viral-mediated MC4R overexpression in the NAc of susceptible mice attenuates social avoidance, providing circuit-level evidence for mood-relevant melanocortin effects.

Learned helplessness (LH): Inescapable footshock followed by shuttle-box escape testing produces escape failure in LH animals. MC4R agonism reduces LH escape latency and failure rate, with the effect blocked by ICV SHU9119.

Inflammation-Mood Interface

Inflammatory depression — characterised by elevated circulating IL-6, TNF-α, and CRP in the context of depressive symptoms — is a recognised phenotype associated with poor SSRI response. Melanocortin peptides, including α-MSH and related compounds, exert potent anti-inflammatory activity via MC1R on peripheral macrophages and MC4R in the CNS on microglia.

Central MC4R agonism suppresses LPS-induced microglial activation (Iba1 morphometry, TNF-α/IL-1β ELISA in hippocampal tissue), reduces sickness behaviour (sucrose preference decline, reduced locomotion) following systemic LPS challenge, and prevents LPS-induced BDNF reduction. This anti-neuroinflammatory profile is mechanistically distinct from monoamine reuptake inhibition and may be particularly relevant in research models of treatment-resistant or inflammation-driven depression.

Sex Differences in Melanocortin Mood Biology

Female rodents show higher baseline sensitivity to MC4R agonism in behavioural assays and elevated MC4R expression in limbic regions at specific oestrous cycle stages. Oestrogen potentiates MC4R-Gs-CREB coupling via genomic ERα interactions with the POMC promoter and via rapid non-genomic membrane signalling. Research designs utilising female subjects should include oestrous cycle staging (vaginal smear cytology) and consider ovariectomised ± oestradiol replacement cohorts to dissect hormonal confounds from direct melanocortin effects.

Research Endpoints and Protocol Design

Behavioural battery for mood-relevant research should include: FST/TST (despair), sucrose preference/SPT anhedonia assessment, open field locomotion/anxiety (centre-time ratio), elevated plus maze (EPM) anxiety index, social interaction test (SI ratio), and where possible a chronic stress paradigm (CUS/CMS 14-21d) for face validity. Molecular endpoints: hippocampal BDNF ELISA/western/qPCR, CREB Ser-133 phospho-immunoblot, TrkB pTyr-705 activation, GluA1 surface expression (biotinylation assay), adult neurogenesis BrdU-NeuN co-labelling (28d BrdU protocol), synaptic density Golgi-Cox/Sholl analysis.

HPA confound controls: corticosterone ELISA (trunk blood at sacrifice, matched time-of-day), adrenal weight, CRH IHC in PVN. Receptor specificity controls: MC4R antagonist co-administration (SHU9119 i.c.v. 50–500 ng), MC4R knockout comparison cohort if feasible.

Selectivity vs Other Melanocortin Compounds

PT-141’s selectivity profile (MC3R/MC4R >> MC1R/MC5R) distinguishes it from Melanotan II (non-selective, including MC1R stimulation producing melanogenesis and MC5R stimulation affecting sebaceous glands) and from Afamelanotide (MC1R-selective, used in EPP photoprotection research). For CNS mood research, this selectivity is advantageous as MC1R peripheral activation confounds (skin pigmentation, melanocyte biology) are minimised, allowing cleaner attribution of central behavioural effects to MC3R/MC4R engagement.

Summary

PT-141 engages MC3R and MC4R within CNS circuits governing mood, reward, and stress reactivity. Downstream Gs-cAMP-CREB-BDNF signalling, monoamine modulation across serotonergic, noradrenergic and dopaminergic systems, and anti-neuroinflammatory activity collectively define a mechanistically multifaceted depression-relevant biology. Preclinical evidence across FST, CUS, SDS, and LH paradigms demonstrates antidepressant-like effects with MC4R receptor specificity established by antagonist blockade and knockout data. Research in this area must account for HPA axis confounds, sex-hormone interactions, and appropriate receptor selectivity controls.